Shares of Savara Inc (NASDAQ:SVRA) have been given an average recommendation of “Buy” by the nine ratings firms that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.60.
A number of equities analysts recently weighed in on SVRA shares. LADENBURG THALM/SH SH reaffirmed a “hold” rating and issued a $1.00 target price on shares of Savara in a research note on Thursday, October 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Savara in a research note on Friday, December 20th. ValuEngine raised shares of Savara from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Finally, Zacks Investment Research raised shares of Savara from a “sell” rating to a “hold” rating in a research note on Friday, November 8th.
A number of large investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in shares of Savara by 11.0% in the 2nd quarter. BlackRock Inc. now owns 2,438,608 shares of the company’s stock valued at $5,779,000 after purchasing an additional 241,117 shares in the last quarter. Nomura Holdings Inc. bought a new stake in Savara during the 2nd quarter valued at $496,000. Marshall Wace North America L.P. bought a new stake in Savara during the 2nd quarter valued at $190,000. Parallax Volatility Advisers L.P. bought a new stake in Savara during the 2nd quarter valued at $189,000. Finally, United Capital Financial Advisers LLC bought a new stake in Savara during the 2nd quarter valued at $61,000. 36.84% of the stock is currently owned by hedge funds and other institutional investors.
SVRA traded down $0.08 during trading on Thursday, hitting $3.70. 6,515 shares of the stock were exchanged, compared to its average volume of 4,450,129. The firm has a market capitalization of $153.30 million, a P/E ratio of -2.86 and a beta of 1.06. Savara has a 1-year low of $0.69 and a 1-year high of $11.96. The stock has a fifty day moving average price of $2.24 and a two-hundred day moving average price of $1.99. The company has a quick ratio of 13.07, a current ratio of 13.07 and a debt-to-equity ratio of 0.23.
Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14. Analysts predict that Savara will post -1.88 EPS for the current year.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
See Also: Google Finance Portfolio
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.